NCT06536023View on ClinicalTrials.gov

This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

July 22, 2025

Study Completion Date

August 1, 2025

Conditions

Adolescents With Obesity

Interventions

DRUG

IBI362

IBI362 SA.QW

DRUG

IBI362 placebo

IBI362 placebo SA.QW

Trial Locations (1)

100045

Beijing Children's Hospital, Capital Medical University Affiliated, Beijin

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06536023 - This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity | Biotech Hunter | Biotech Hunter